FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:2286-2289 November 20, 2008 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Piot, C. PubMed Citation

To the Editor: In the article by Piot et al. (July 31 issue),¹ cyclosporine, an inhibitor of the mitochondrial permeability transition, decreased infarct size after percutaneous coronary intervention (PCI) when administered just before the procedure. Although promising, cyclosporine has drawbacks, including immunosuppression, nephrotoxicity, and variable bioavailability. Cyclosporine is effective at lower concentrations (0.5 to 2 µM), but protection is lost at higher concentrations (5 µM); thus the drug has a narrow therapeutic window.² Nonimmunosuppressive analogues of cyclosporine, such as NIM811, seem not to lose efficacy at high doses and might be more suitable for PCI.³ Other drugs block the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.